OEM Dolutegravir capsule Anti-Virul Dolutegravir powder Raw Material Dolutegravir
Product Description
Product Datails
Chemical Name |
Dolutegravir |
CAS NO. |
1051375-19-9 |
Appearance |
Powder or liquid |
Molecular Formula |
C20H18F2N3NaO5 |
Molecular Weight |
441.36100 |
Dolutegravir (Dolutegravir, Tivicay) is a new anti-AIDS drug developed by the British pharmaceutical giant GlaxoSmithKline (GSK) and Japan's Shionogi Pharmaceutical Company (Shionogi). In July 2012, GlaxoSmithKline Pharmaceuticals and Shionoyoshi Pharmaceuticals announced the results of the Phase III clinical trial of the new AIDS drug Dolutegravir. After receiving dolutegravir and two other old-version AIDS drugs for 48 weeks, 88% of the patients' bodies The virus was successfully suppressed, and Gilead Sciences' three-in-one oral drug Atripla (Efavirenz/Emtricitabine/TenofovirDisoproxilFumarate) After that, 81% of the virus in the patient's body was suppressed. It can be seen that the dolutegravir drug of GlaxoSmithKline is slightly better. According to the researchers, in the comparison trial, due to the side effects of the drug, 10% of the patients eventually stopped taking Gilead's Atripla drug, but only 2% of the patients stopped taking GlaxoSmithKline's dolutegravir. Drugs, it can be seen that the safety of GlaxoSmithKline dolutegravir is slightly higher.
Application&Function
Dulutvir sodium salt is a second-generation HIV-1 integrase chain transfer inhibitor. Dulutvir sodium is currently in phase III clinical trials for the treatment of HIV infection. It has been shown that Dulutvir Chemicalbook sodium salt can effectively inhibit HIV replication in cells infected with inactivated PHIV lentiviral vectors (such as peripheral blood mononuclear cells (PBMC), MT-4 cells and CIP4 cells).
Specification